A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis

Inclusion criteria

• Voluntarily sign the informed consent form before starting the activities related to the trial;
• The Numerical Evaluation Scale (NRS) pain score of the index knee joint at screening is ≥ 4;
• Subjects must be willing to discontinue all medical and non-medical treatments for osteoarthritis pain except rescue medication (acetaminophen) and not use prohibited analgesics throughout the study ;
• Male and female subjects of childbearing potential must agree to use highly effective contraceptive measures with their partners from the signing of the informed consent form until 1 month after the last dose of investigational product.

Exclusion criteria

• History of other diseases that may involve the target joint;
• History of major trauma or surgery of knee joint and hip joint in the past year;
• Plan to undergo surgical procedure during the study;
• Most or complete loss of mobility;
• There are other diseases that may confuse the assessment of osteoarthritis pain;
• There is a neuropsychiatric disease, and the investigator's assessment may affect the evaluation of osteoarthritis (OA) or self-score;
• There are serious or poorly controlled concomitant diseases;
• Those who have a clear history of peptic ulcer, bleeding, perforation or obstruction within 1 year before screening, and have been clinically diagnosed;
• Those who require drug treatment or surgical intervention;
• History of malignant tumors within 5 years before screening;
• Have a history of drug abuse, drug abuse and/or alcoholism within 2 years before screening.